Drugs / Dichloroacetate Sodium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01083524 | Mar 2010 → Sep 2013 | pulmonary arterial hypertension | University of Alberta | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dichloroacetate Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01083524 ↗ |
| Action | Inhibit | “the small molecular DCA, an inhibitor of the mitochondrial enzyme pyruvate dehydrogenase kinase” NCT01083524 ↗ |
| Modality | Small molecule | “The small molecule and metabolic modulator Dichloroacetate (DCA)” NCT01083524 ↗ |
| Route | Oral | “12.5 mg po bid” NCT01083524 ↗ |